Drug developer GW Pharma to cancel London listing



Britain's GW Pharmaceuticals Plc, a developer of marijuana-based epilepsy treatments, said it planned to cancel its listing in London's junior market and would retain listing of its American Depositary Receipts (ADRs) on Nasdaq to simplify trading and cut expenses of dual listing.
The pharmaceutical company, which listed on London Stock Exchange's Alternative Investment Market (AIM) in June 2001, said it would remain headquartered in the UK and would continue to expand its operations in the country.
"With the vast majority of shares now held and traded in the U.S. in the form of ADRs,... read more

 
19 October 2016 in Business, Views: 36
Source: Reuters
Share:
  •  





    News Widget for Webmasters



    Bring Eugene's son back home immediately

    Realtime News

     

    «
    »
    Mo Tu We Th Fr Sa Su
          1 2 3 4
    5 6 7 8 9 10 11
    12 13 14 15 16 17 18
    19 20 21 22 23 24 25
    26 27 28 29 30 31